Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2026-01-14 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于召开2026年第一次临时股东会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2026 first extraordinary general meeting of shareholders (临时股东会通知公告). It details the meeting date, voting methods (including online voting), eligibility, agenda items, registration procedures, and contact information. It does not contain financial statements, audit results, or detailed financial data. It is not a report itself but an announcement about a shareholders meeting. The document length is 2667 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and not the voting results or proxy materials, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about the meeting. The document does not fit the criteria for other more specific categories such as AGM Information (AGM-R) because it is an extraordinary meeting, not an annual general meeting, and it is not a presentation or materials shared during the meeting. Hence, the most appropriate classification is Regulatory Filings (RNS).
2026-01-14 Chinese
关于部分募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the completion of certain fundraising investment projects and the permanent allocation of surplus raised funds to supplement working capital. It details the fundraising amount, project investment status, surplus funds, and the board's approval process. The document is a formal disclosure about the use and management of raised capital, including regulatory compliance and board resolutions. It does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or legal proceeding update. It is specifically about the use of capital raised through stock issuance and the reallocation of surplus funds, which fits the definition of a Capital/Financing Update (CAP). The document length is about 4,886 characters, which is sufficient for a substantive announcement rather than a brief notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-01-14 Chinese
平安证券股份有限公司关于四川梓橦宫药业股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Ping An Securities Co., Ltd. acting as the sponsor institution for Sichuan Zizhuanggong Pharmaceutical Co., Ltd. It discusses the completion of certain fundraising investment projects and the permanent supplementation of surplus raised funds into working capital. The document includes detailed financial figures about the raised funds, their usage, storage, investment projects, surplus funds, and the company's board resolutions approving these actions. It references regulatory rules related to fundraising management and includes the sponsor's verification opinion. The content is focused on the use and management of raised capital, not a general financial report or earnings release. It is not a simple announcement but a thorough verification and opinion report on fundraising project completion and fund usage. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (5930 characters) and detailed financial data support this classification rather than a brief announcement or regulatory filing. Therefore, the filing type is CAP with high confidence.
2026-01-14 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase entrusted financial products. It details the amounts, types, counterparties, expected yields, and risk controls related to these financial investments. The document is relatively short (3080 characters) and focuses on a specific financing activity rather than presenting comprehensive financial statements or results. It does not contain full financial reports or earnings data but rather an update on capital management activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-01-14 Chinese
关于收到8个药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the receipt of 8 drug re-registration approval notices issued by the Sichuan Provincial Drug Administration. It lists the drug names, specifications, approval numbers, and validity periods. The document includes a risk warning and states the positive impact of these approvals on the company's production qualifications. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no capital or financing updates, and no legal proceedings. The document is an official announcement about regulatory approvals related to the company's products. It is not a report, transcript, or financial filing. Given the nature of the content and the absence of other fitting categories, this falls under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-28 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement from a company about the progress of using its own idle funds for entrusted financial management, specifically purchasing low-risk short-term financial products. It includes details about the amounts, counterparties, risk controls, and compliance with stock exchange rules. The document is relatively short (3243 characters) and focuses on a specific financing activity rather than comprehensive financial results or management discussion. It is not an annual or interim report, nor an earnings release, nor a regulatory certification. It is an update on capital usage and financing activities related to entrusted financial management. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-12-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.